Oral peptide GLP-1 receptor agonist
Semaglutide oral once daily (original tablet), flexible dose: 3, 7 or 14 mg adjusted by HbA1c and tolerability
SEMA_PO_FLEX_QD
For example PIONEER 7. Sensitivity analysis assigns the arm to 14 mg. A flexible regimen with a different formulation, permitted dose set or adjustment algorithm is a different node.
Related
- All doses pooled: Semaglutide tablet
- Semaglutide 14 mg oral once daily (original tablet)
- Semaglutide 20 mg tablet once daily
- Semaglutide 40 mg tablet once daily
- Semaglutide 3 mg oral once daily (original tablet)
- Semaglutide 7 mg oral once daily (original tablet)
- Semaglutide 50 mg oral once daily (higher dose oral program)
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.37 (-0.10 to 0.89) | 0.26 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.84 (-1.52 to 0.02) | 0.68 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.99 (-3.64 to 2.39) | 0.48 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.62 (-5.11 to 0.15) | 0.76 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 7.78 (1.40 to 22.25) | 0.88 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.12 (-2.94 to 9.16) | 0.49 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -5.73 (-14.57 to 4.33) | 0.83 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -3.28 (-6.88 to 1.06) | 0.76 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.83 (0.91 to 17.16) | 0.85 |